Efficacy and Safety of Ivermectin Against Dengue Infection

Summary

This is a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Ivermectin in Children and Adult patients with Dengue Infection.

Timeline

Start

2014-02

Primary completion

2016-02

Completion

2016-03

Publications

• Kawuma AN, Ojara FW, Buzibye A, Castelnuovo B, Tabwenda JC, Kyeyune J, Turyahabwe C, Asiimwe SP, Magoola J, Wiesner L, Nakijoba R, Waitt C. Interim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother-infant pairs. CPT Pharmacometrics Syst Pharmacol. 2024 Nov;13(11):1915-1923. doi: 10.1002/psp4.13247. Epub 2024 Oct 2.
• Ding J, Mairiang D, Prayongkul D, Puttikhunt C, Noisakran S, Kaewjiw N, Songjaeng A, Prommool T, Tangthawornchaikul N, Angkasekwinai N, Suputtamongkol Y, Lapphra K, Chokephaibulkit K, White NJ, Avirutnan P, Tarning J. In-host modeling of dengue virus and non-structural protein 1 and the effects of ivermectin in patients with acute dengue fever. CPT Pharmacometrics Syst Pharmacol. 2024 Dec;13(12):2196-2209. doi: 10.1002/psp4.13233. Epub 2024 Sep 23.
• Ooi EE. Repurposing Ivermectin as an Anti-dengue Drug. Clin Infect Dis. 2021 May 18;72(10):e594-e595. doi: 10.1093/cid/ciaa1341. No abstract available.

Drugs

Indications